| Description |
1 online resource |
| Series |
Progress in inflammation research |
|
PIR (Series)
|
| Contents |
Preface; Contents; List of Contributors; About the Editor; Part I: Diagnosis, Patient Stratification and Biomarkers; A Tale of Two Worlds; 1 Introduction; 2 The Many Faces of a Diagnosis; 3 Heterogeneity; 3.1 Prevalence of Heterogeneity; 3.2 Heterogeneity Due to Overlap; 3.2.1 Simultaneous; 3.2.2 Evolving Overlap; 3.2.3 Overlap with Non-rheumatic Autoimmune Illness; 3.2.4 Overlap That Does Not Meet Criteria; 3.3 Heterogeneity Due to Inapplicable Diagnosis and Treatment Guidelines; 4 Physician Inconsistency; 4.1 Inconsistent Diagnoses; 4.2 Inconsistent Treatment; 5 Effect of Time |
|
6 Variables Not Considered in Disease Activity, Severity, and Damage Scales7 The Problem with Mice as Proxies for Human Disease Measures; 8 What Is Precise Diagnosis?; 9 Proposals; 9.1 Stratify Patient Populations by Disease Process, Not by Diagnosis; 9.2 Seek Larger, Simpler Databases; References; Biomarkers in Clinical Trials for Rheumatoid Arthritis; 1 Introduction; 2 What Are Biomarkers?; 3 Biomarkers Currently Used in Rheumatoid Arthritis Clinical Trials; 3.1 Biomarkers as Inclusion Criteria for Clinical Trials; 4 Use of CRP or ESR in Clinical Trials for Rheumatoid Arthritis |
|
5 Diagnostic Biomarkers6 Rheumatoid Factor; 7 Anti-citrullinated Protein Antibodies; 8 14-3-3; 8.1 Disease Activity Biomarkers in RA; 9 Vectra® DA; 10 Validation of Rheumatoid Arthritis Biomarkers; 11 Technological Advancements in Testing for Biomarkers; 12 Main Challenges in Biomarker Discovery; 13 Emerging Trends in Biomarkers; 14 Potential Investment Required for Use in Clinical Trials; 15 Ethical and Legal Considerations; 16 Conclusion; References; The Role of Microparticles as Biomarkers in the Development of Therapy for Autoimmune Disease; 1 Introduction; 2 Generation of Microparticles |
|
3 The Assay of Microparticles4 The Functions of Microparticles; 5 MPs as a Source of DAMPs and Alarmins; 6 Microparticles as a Source of Immune Complexes; 7 Implications for New Therapies; 8 Conclusions; References; Part II: Genomic Medicine; The Future for Genomic Medicine in Inflammatory Diseases; 1 Expanding the Druggable Target Universe; 2 A Brief History of Genomic Modalities; 2.1 Antisense; 2.2 RNA Interference; 2.3 MicroRNA; 2.4 Gene Therapy; 2.5 Genome Editing; 3 State of the Art in Genomic Medicine; 4 Barriers to Successful Gene Therapy: Cystic Fibrosis as a Case Study |
|
5 The Rise and Fall and Rise of Genomic Medicine in the Pharma and Biotech Sectors6 Genomic Medicine and Inflammatory Diseases; 7 Converting the Promise of Genomic Medicine into Reality for Inflammatory Diseases; 7.1 Delivery; 7.2 Target; 7.3 Development Path; 7.4 Target Regulation; 7.5 Control of Expression; 7.6 Superior Efficacy Versus Standard of Care; 7.7 Costs; 8 Summary; References; Part III: Bispecific Antibodies; Bispecific Antibodies; 1 Introduction; 2 Rationale for Bispecific Biologics in Rheumatoid Arthritis; 2.1 Mode of Action of Biologics in RA and Combination Therapies |
| Summary |
As our understanding of immune mediated chronic inflammatory diseases (IMIDs) grows, it becomes more and more clear that these conditions result from the convergence of a multitude of pathogenic mechanisms whose relative individual contribution is different in different patient subsets. Promising new technologies have been conceived that address the hypotheses that targeting multiple pathways simultaneously, selectively delivering therapeutics to areas of inflammation and/or resetting the immune system, could take efficacy to new levels. However, we have long waited for the arrival of some of these technologies to the bedside, or even far enough in the drug development process in spite of the initial enthusiasm. Some of the examples covered in this book include bispecific antibodies and genomic medicines, microparticles and targeted delivery of drugs to inflamed vasculature. Most published reviews and book chapters on novel therapies for inflammatory diseases describe positive attributes of molecules or technologies under investigation and the rationale for developing them into therapeutics. The originality and potential value of this book is not in the description of these targets or technologies from the point of view of their structure or mechanism of action exclusively, but rather, in making an effort to critically address the question of what is needed to move these technologies into the clinic. Has the technology not made it past the preclinical stage and why? Has it already been tested in humans and failed? What are the potential reasons behind those failures? What do experts in each field believe can be done better to increase the probabilities of success? In addition, the authors address the competitive landscape and summarize clinical studies that have failed in the respective area. They talk about the patient populations that would be required for the successful conduction of a clinical trial to test certain molecules, and they proactively share their views regarding both the potential and the drawbacks of targets or methodologies |
| Bibliography |
Includes bibliographical references and index |
| Notes |
Online resource; title from PDF title page (SpringerLink, viewed February 3, 2017) |
| Subject |
Inflammation -- Immunological aspects.
|
|
Immune System Diseases -- therapy
|
|
Pharmaceutical technology.
|
|
Medical genetics.
|
|
Pharmacy -- dispensing.
|
|
Immunology.
|
|
MEDICAL -- Pathology.
|
|
Inflammation -- Immunological aspects
|
| Form |
Electronic book
|
| Author |
Mina-Osorio, Paola, editor
|
| ISBN |
9783319422527 |
|
3319422529 |
|
